TAPAZOLE

Tapazole Adverse Events Reported to the FDA Over Time

How are Tapazole adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tapazole, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tapazole is flagged as the suspect drug causing the adverse event.

Most Common Tapazole Adverse Events Reported to the FDA

What are the most common Tapazole adverse events reported to the FDA?

Pyrexia	18 (1.69%)
Asthenia	17 (1.6%)
Headache	17 (1.6%)
Agranulocytosis	16 (1.5%)
Drug Exposure During Pregnancy	13 (1.22%)
Arthralgia	12 (1.13%)
Hypothyroidism	12 (1.13%)
Dyspnoea	11 (1.03%)
Fatigue	11 (1.03%)
Myalgia	11 (1.03%)
Nausea	11 (1.03%)
	Show More
Thrombocytopenia	11 (1.03%)
Choanal Atresia	10 (.94%)
Jaundice	10 (.94%)
Completed Suicide	9 (.85%)
Drug Interaction	9 (.85%)
Paraesthesia	9 (.85%)
Alanine Aminotransferase Increased	8 (.75%)
Heart Rate Increased	8 (.75%)
Hypoaesthesia	8 (.75%)
Increased Upper Airway Secretion	8 (.75%)
Malaise	8 (.75%)
Product Tampering	8 (.75%)
Rash	8 (.75%)
Urticaria	8 (.75%)
Vomiting	8 (.75%)
White Blood Cell Count Decreased	8 (.75%)
Abdominal Pain Upper	7 (.66%)
Anaemia	7 (.66%)
Blood Bilirubin Increased	7 (.66%)
Blood Glucose Increased	7 (.66%)
Dysgeusia	7 (.66%)
Pain	7 (.66%)
Tri-iodothyronine Increased	7 (.66%)
Weight Decreased	7 (.66%)
Diabetes Mellitus	6 (.56%)
Dry Eye	6 (.56%)
Exomphalos	6 (.56%)
Feeling Abnormal	6 (.56%)
Haematocrit Decreased	6 (.56%)
Hepatitis Acute	6 (.56%)
Hunger	6 (.56%)
Metabolic Acidosis	6 (.56%)
Muscular Weakness	6 (.56%)
Polyuria	6 (.56%)
Pruritus	6 (.56%)
Rash Pruritic	6 (.56%)
Thirst	6 (.56%)
Weight Increased	6 (.56%)
Alopecia	5 (.47%)
Aspartate Aminotransferase Increase...	5 (.47%)
Blood Alkaline Phosphatase Increase...	5 (.47%)
Blood Thyroid Stimulating Hormone I...	5 (.47%)
Cardio-respiratory Arrest	5 (.47%)
Delayed Fontanelle Closure	5 (.47%)
Drug Ineffective	5 (.47%)
Dysphagia	5 (.47%)
Gastric Haemorrhage	5 (.47%)
Haemoglobin Decreased	5 (.47%)
Leukopenia	5 (.47%)
Neutropenia	5 (.47%)
Ocular Icterus	5 (.47%)
Pain In Extremity	5 (.47%)
Renal Failure	5 (.47%)
Renal Failure Acute	5 (.47%)
Splenic Infarction	5 (.47%)
Abdominal Pain	4 (.38%)
Ageusia	4 (.38%)
Anaphylactic Reaction	4 (.38%)
Anti-neutrophil Cytoplasmic Antibod...	4 (.38%)
Anxiety	4 (.38%)
Back Pain	4 (.38%)
Breast Cyst	4 (.38%)
Chills	4 (.38%)
Coordination Abnormal	4 (.38%)
Dental Caries	4 (.38%)
Dysmorphism	4 (.38%)
Glomerulonephritis	4 (.38%)
Haemorrhage	4 (.38%)
Hepatitis Cholestatic	4 (.38%)
International Normalised Ratio Incr...	4 (.38%)
Micturition Disorder	4 (.38%)
Musculoskeletal Chest Pain	4 (.38%)
Oropharyngeal Pain	4 (.38%)
Pharyngeal Disorder	4 (.38%)
Platelet Count Decreased	4 (.38%)
Post Procedural Haemorrhage	4 (.38%)
Product Container Seal Issue	4 (.38%)
Rhabdomyolysis	4 (.38%)
Stevens-johnson Syndrome	4 (.38%)
Tooth Disorder	4 (.38%)
Tremor	4 (.38%)
Activated Partial Thromboplastin Ti...	3 (.28%)
Acute Myeloid Leukaemia	3 (.28%)
Angioedema	3 (.28%)
Aplasia Cutis Congenita	3 (.28%)
Areflexia	3 (.28%)
Central Nervous System Lesion	3 (.28%)
Clinodactyly	3 (.28%)
Decreased Appetite	3 (.28%)
Developmental Delay	3 (.28%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Tapazole, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tapazole is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tapazole

What are the most common Tapazole adverse events reported to the FDA?

Neurological	55 (5.17%)
Gastrointestinal Signs	42 (3.95%)
Epidermal And Dermal Conditions	39 (3.67%)
Hematology Investigations	39 (3.67%)
Respiratory	36 (3.38%)
Hepatic And Hepatobiliary	32 (3.01%)
White Blood Cell	29 (2.73%)
Hepatobiliary	27 (2.54%)
Muscle	26 (2.44%)
Urinary Tract Signs	21 (1.97%)
Body Temperature Conditions	18 (1.69%)
	Show More
Headaches	18 (1.69%)
Joint	18 (1.69%)
Renal Disorders	17 (1.6%)
Therapeutic And Nontherapeutic Effe...	17 (1.6%)
Chemical Injury And Poisoning	16 (1.5%)
Thyroid Gland	16 (1.5%)
Endocrine Investigations	14 (1.32%)
Gastrointestinal Tract Disorders Co...	13 (1.22%)
Musculoskeletal And Connective Tiss...	13 (1.22%)
Physical Examination Topics	13 (1.22%)
Product Quality Issues	13 (1.22%)
Platelet	12 (1.13%)
Angiedema And Urticaria	11 (1.03%)
Cardiac And Vascular Investigations	11 (1.03%)
Cardiac Arrhythmias	11 (1.03%)
Eye	11 (1.03%)
Injuries	11 (1.03%)
Movement Disorders	11 (1.03%)
Musculoskeletal And Connective Tiss...	11 (1.03%)
Respiratory Disorders Congenital	11 (1.03%)
Suicidal And Self-injurious Behavio...	11 (1.03%)
Anemias Nonhemolytic And Marrow Dep...	10 (.94%)
Upper Respiratory Tract Disorders	10 (.94%)
Gastrointestinal Hemorrhages	9 (.85%)
Allergic Conditions	8 (.75%)
Dental And Gingival Conditions	8 (.75%)
Metabolic, Nutritional And Blood Ga...	8 (.75%)
Anxiety Disorders	7 (.66%)
Bacterial Infectious	7 (.66%)
Immunology And Allergy	7 (.66%)
Musculoskeletal And Connective Tiss...	7 (.66%)
Acid-base	6 (.56%)
Appetite And General Nutritional	6 (.56%)
Changes In Physical Activity	6 (.56%)
Glucose Metabolism Disorders	6 (.56%)
Infections - Pathogen Unspecified	6 (.56%)
Lower Respiratory Tract Disorders	6 (.56%)
Nephropathies	6 (.56%)
Ocular Infections, Irritations And ...	6 (.56%)
Oral Soft Tissue Conditions	6 (.56%)
Skin Vascular Abnormalities	6 (.56%)
Disturbances In Thinking	5 (.47%)
Ear And Labyrinthine Disorders Cong...	5 (.47%)
Enzyme	5 (.47%)
Medication Errors	5 (.47%)
Peripheral Neuropathies	5 (.47%)
Skin And Subcutaneous Tissue Disord...	5 (.47%)
Skin Appendage Conditions	5 (.47%)
Sleep Disorders	5 (.47%)
Spleen, Lymphatic And Reticulendoth...	5 (.47%)
Breast	4 (.38%)
Cardiac Disorder Signs	4 (.38%)
Exocrine Pancreas Conditions	4 (.38%)
Gastrointestinal Stenosis And Obstr...	4 (.38%)
Immune	4 (.38%)
Ocular Neuromuscular	4 (.38%)
Procedural And Device Related Injur...	4 (.38%)
Vascular Hemorrhagic	4 (.38%)
Congenital And Hereditary	3 (.28%)
Eye Disorders Congenital	3 (.28%)
Fungal Infectious	3 (.28%)
Heart Failures	3 (.28%)
Leukemias	3 (.28%)
Menstrual Cycle And Uterine Bleedin...	3 (.28%)
Neonatal And Perinatal Conditions	3 (.28%)
Neuromuscular	3 (.28%)
Psychiatric	3 (.28%)
Seizures	3 (.28%)
Breast Neoplasms Malignant And Unsp...	2 (.19%)
Bronchial Disorders	2 (.19%)
Cardiac And Vascular Disorders Cong...	2 (.19%)
Central Nervous System Vascular	2 (.19%)
Cranial Nerve Disorders	2 (.19%)
Decreased And Nonspecific Blood Pre...	2 (.19%)
Electrolyte And Fluid Balance Condi...	2 (.19%)
Gallbladder	2 (.19%)
Gastrointestinal Motility And Defec...	2 (.19%)
Gastrointestinal Neoplasms Benign	2 (.19%)
Immunodeficiency Syndromes	2 (.19%)
Increased Intracranial Pressure And...	2 (.19%)
Lipid Analyses	2 (.19%)
Lymphomas	2 (.19%)
Malabsorption Conditions	2 (.19%)
Mental Impairment	2 (.19%)
Metastases	2 (.19%)
Mood Disorders	2 (.19%)
Neonatal Respiratory	2 (.19%)
Obstetric And Gynecological Therape...	2 (.19%)
Ocular Structural Change, Deposit A...	2 (.19%)
Pigmentation	2 (.19%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tapazole, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tapazole is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.